Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Earnings for Bellerophon Therapeutics, Inc. (BLPH)
Earnings in 2022 (TTM): $-22,248,000
According to Bellerophon Therapeutics, Inc.'s latest financial reports the company's current earnings (TTM) are $-22,248,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Bellerophon Therapeutics, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-22,248,000 | $-19,831,000 |
| 2021 | $-19,556,000 | $-17,756,000 |
| 2020 | $-26,853,000 | $-24,728,000 |
| 2019 | $-15,068,000 | $-13,267,000 |
| 2018 | $-2,625,000 | $2.81 M |
| 2017 | $-54,818,000 | $-54,818,000 |
| 2016 | $-24,252,000 | $-23,814,000 |
| 2015 | $-46,459,000 | $-46,459,000 |
| 2014 | $-59,674,000 | $-59,674,000 |
| 2013 | $-61,998,000 | $-61,998,000 |
| 2012 | $-46,227,000 | $-46,227,000 |